Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic γδ T Cells in Resectable Melanoma
NCT06212388Phase 1Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Jan 2024
- Primary completion
- Oct 2027
- Modality
- Prophylactic Vaccines, Cell Therapies, Therapeutic Vaccines
01
Overview
Phase 1, randomised, open-label trial of allogeneic gamma-delta T cells in melanoma (2 arms), sponsored by Xijing Hospital. Primary endpoints: Pathological Complete Response Rate at 12 weeks, Major Pathological Response Rate at 12 weeks and 3 more. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
allogeneic gamma-delta T cells
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06212388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06212388.